Literature DB >> 18397226

Predictors of a sustained virological response in patients with genotype 4 chronic hepatitis C.

Rita Raafat Gad1, Sylvia Males, Hesham El Makhzangy, Soheir Shouman, Aboubakr Hasan, Mohamed Attala, Mostafa El Hoseiny, Khaled Zalata, Mohamed Abdel-Hamid, Arnaud Fontanet, Mostafa K Mohamed, Gamal Esmat.   

Abstract

OBJECTIVES: To determine the clinical, biological, virological and histological predictive factors associated with a sustained virological response (SVR) to combined interferon therapy among Egyptian patients infected by genotype 4 hepatitis C virus (HCV). PATIENTS AND METHODS: Individual data from 250 patients with genotype 4 chronic hepatitis C, treated with different regimens of combined interferon, were analysed. The primary end point was SVR defined as undetectable HCV RNA by polymerase chain reaction (PCR) 24 weeks after the end of treatment. Multivariate logistic regression analysis was performed to select the independent prognostic parameters associated with SVR.
RESULTS: A sustained virological response was achieved among 137/250 (54.8%) patients. Baseline factors independently and negatively associated with SVR were serum alpha-fetoprotein (AFP) level (above 0.3 upper limit of normal) [odds ratio (OR)=0.5, 95% confidence interval (CI): 0.2-0.8], severe fibrosis (Metavir score >F2) (OR=0.4, 95% CI: 0.2-0.8), presence of steatosis (OR=0.5, 95% CI: 0.3-0.97) and standard interferon treatment (OR=0.4, 95% CI: 0.2-0.8).
CONCLUSIONS: Among genotype 4 chronic hepatitis C patients, severe fibrosis, severe steatosis, treatment with standard interferon and a high serum AFP level were all negatively associated with SVR. Pretreatment serum AFP level should be considered in the routine assessment of factors predictive of a treatment response.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18397226     DOI: 10.1111/j.1478-3231.2008.01750.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  11 in total

Review 1.  Current status and emerging challenges in the treatment of hepatitis C virus genotypes 4 to 6.

Authors:  Vasilios Papastergiou; Stylianos Karatapanis
Journal:  World J Clin Cases       Date:  2015-03-16       Impact factor: 1.337

2.  Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis.

Authors:  Masayuki Kurosaki; Naoya Sakamoto; Manabu Iwasaki; Minoru Sakamoto; Yoshiyuki Suzuki; Naoki Hiramatsu; Fuminaka Sugauchi; Hiroshi Yatsuhashi; Namiki Izumi
Journal:  J Gastroenterol       Date:  2010-09-10       Impact factor: 7.527

Review 3.  Pathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of a successful pathogen.

Authors:  Amedeo Lonardo; Luigi Elio Adinolfi; Luciano Restivo; Stefano Ballestri; Dante Romagnoli; Enrica Baldelli; Fabio Nascimbeni; Paola Loria
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

4.  Meta-analysis: influence of host and viral factors in patients with chronic hepatitis C genotype 4 treated with pegylated interferon and ribavirin.

Authors:  Brittany E Yee; Nghia H Nguyen; Bing Zhang; Philip Vutien; Carrie R Wong; Glen A Lutchman; Mindie H Nguyen
Journal:  Eur J Gastroenterol Hepatol       Date:  2014-11       Impact factor: 2.566

5.  Sustained virological response and its treatment predictors in hepatitis C virus genotype 4 compared to genotypes 1, 2, and 3: a meta-analysis.

Authors:  Brittany E Yee; Nghia H Nguyen; Bing Zhang; Derek Lin; Philip Vutien; Carrie R Wong; Glen A Lutchman; Mindie H Nguyen
Journal:  BMJ Open Gastroenterol       Date:  2015-07-09

6.  Gelatin nanoparticles enhance delivery of hepatitis C virus recombinant NS2 gene.

Authors:  Salwa Sabet; Marina A George; Haidan M El-Shorbagy; Heba Bassiony; Khaled Y Farroh; Tareq Youssef; Taher A Salaheldin
Journal:  PLoS One       Date:  2017-07-26       Impact factor: 3.240

7.  Predictors of sustained virologic response in hepatitis C genotype 4: beyond the usual suspects.

Authors:  Ayman A Abdo; Faisal M Sanai
Journal:  Ann Saudi Med       Date:  2009 Jan-Feb       Impact factor: 1.526

8.  Prediction of sustained virologic responses to combination therapy of pegylated interferon-α and ribavirin in patients with chronic hepatitis C infection.

Authors:  Mona H Ismail
Journal:  J Family Community Med       Date:  2013-01

9.  Human leukocyte antigen class II alleles (DQB1 and DRB1) as predictors for response to interferon therapy in HCV genotype 4.

Authors:  Olfat Shaker; Heba Bassiony; Maissa El Raziky; Samer S El-Kamary; Gamal Esmat; Akmal M El-Ghor; Mona M Mohamed
Journal:  Mediators Inflamm       Date:  2013-03-14       Impact factor: 4.711

10.  The impact of interleukin 28b gene polymorphism on the virological response to combined pegylated interferon and ribavirin therapy in chronic HCV genotype 4 infected egyptian patients using data mining analysis.

Authors:  Marwa Khairy; Rabab Fouad; Mahassen Mabrouk; Wafaa El-Akel; Abu Bakr Awad; Rabab Salama; Mayada Elnegouly; Olfat Shaker
Journal:  Hepat Mon       Date:  2013-07-17       Impact factor: 0.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.